3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 – Annals of Oncology

Original Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma

Related: Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.